View Older Stories

Jan 16, 2026 07:07AM Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald

Jan 13, 2026 09:07AM 'Arrowhead Pharma (ARWR) Raises $930 Million to Launch Redemplo'; PT Raised at Piper Sandler

Jan 12, 2026 05:05PM Arrowhead Pharmaceuticals raises $700 million in convertible notes

Jan 7, 2026 08:36AM Bernstein on Arrowhead Pharma (ARWR): 'Obesity Data Meets Our Solid Win Scenario'

Jan 7, 2026 07:45AM Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald

Jan 7, 2026 07:32AM Arrowhead receives China approval for rare disease drug REDEMPLO

Jan 7, 2026 04:16AM Arrowhead Pharma (ARWR) PT Raised to $84 at BofA Securities

Jan 7, 2026 03:58AM Goldman Sachs Reiterates Neutral Rating on Arrowhead Pharma (ARWR)

Jan 6, 2026 07:30AM Arrowhead Pharmaceuticals reports interim obesity drug trial results

Jan 5, 2026 07:30AM Health Canada approves Arrowhead's REDEMPLO for rare triglyceride disorder

Jan 2, 2026 08:22AM Arrowhead Pharma (ARWR) PT Raised at Bernstein Ahead of Obesity Data Update

Dec 23, 2025 05:30PM Jefferies lists 5 biotech M&A candidates for 2026

Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note

Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026

Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'

Dec 17, 2025 06:56AM Piper Sandler Names Arrowhead Pharma (ARWR) 'A Top Pick for 2026', Lifts Stock PT

Dec 11, 2025 06:06AM Arrowhead Pharmaceuticals Inc. (ARWR) files mixed shelf

Dec 11, 2025 05:59AM Arrowhead Pharma (ARWR) PT Raised to $80 at RBC Capital

Dec 3, 2025 06:42AM Arrowhead Pharma (ARWR) PT Raised to $85 at H.C. Wainwright

Dec 1, 2025 06:26AM Arrowhead Pharma (ARWR) PT Raised to $62 at BofA Securities

Nov 24, 2025 07:30AM Arrowhead Pharmaceuticals receives $200 million from Sarepta milestone

Nov 19, 2025 09:14AM TD Cowen on Arrowhead Pharma (ARWR): 'Momentum Is Strong; Buy'

Nov 19, 2025 09:06AM Arrowhead Pharma (ARWR) PT Raised at RBC Capital Following Redemplo Approval

Nov 19, 2025 08:51AM Arrowhead Pharma (ARWR) PT Raised at Piper Sandler Following FDA Approval

Nov 19, 2025 07:28AM Arrowhead Pharma's (ARWR) Redemplo Approved in FCS - Cantor Fitzgerald

Nov 19, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Nov 18, 2025 12:15PM Arrowhead Pharmaceuticals Inc. (ARWR) resumes trading

Nov 18, 2025 11:17AM FDA approves Arrowhead's Redemplo to reduce triglycerides in adults with familial chylomicronemia syndrome

Nov 18, 2025 11:14AM Arrowhead Pharmaceuticals Inc. (ARWR) halted, news pending

Nov 11, 2025 04:23PM Arrowhead Pharma (ARWR) PT Raised to $45 at Morgan Stanley

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

Oct 8, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Oct 7, 2025 07:31AM Arrowhead files application for dual-gene RNAi therapy trial

Sep 11, 2025 07:30AM Arrowhead files lawsuit against Ionis over plozasiran patent dispute

Sep 3, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Sep 2, 2025 07:30AM Arrowhead Pharmaceuticals partners with Novartis for $200 million deal

Aug 13, 2025 04:10PM Arrowhead receives $100 million milestone from Sarepta in mixed payment

Aug 8, 2025 08:24AM Arrowhead Pharma (ARWR) PT Lowered to $21 at Leerink Partners

Aug 7, 2025 04:02PM Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 40c

Aug 1, 2025 06:30AM Sanofi acquires rights to plozasiran drug candidate in Greater China

Jul 28, 2025 07:30AM Arrowhead receives $100 million milestone from Sarepta for ARO-DM1 study

Jul 21, 2025 03:34PM Arrowhead Pharmaceuticals Inc. (ARWR) call put ratio 8 calls to 1 put with a focus on September 17 calls as share price is down 12%

Jul 8, 2025 07:30AM Arrowhead starts phase 3 trial for rare cholesterol disorder drug

May 13, 2025 09:42AM Arrowhead Pharma (ARWR) PT Lowered to $40 at RBC Capital

May 13, 2025 07:51AM Cantor Fitzgerald Reiterates Overweight Rating on Arrowhead Pharma (ARWR)

May 13, 2025 04:52AM Arrowhead Pharma (ARWR) PT Lowered to $17 at Citi

May 12, 2025 04:04PM Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c

Apr 15, 2025 04:01PM Arrowhead Pharmaceuticals Inc. (ARWR) Appoints Daniel Apel as CFO

Mar 11, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Mar 10, 2025 02:18PM Goldman Sachs Reiterates Neutral Rating on Arrowhead Pharma (ARWR)

View Older Stories